Similar articles for PMID: 16084146

Year	Number of Results
1954	1
1963	1
1973	1
1983	1
1993	1
1994	1
1995	1
1998	1
1999	1
2001	3
2002	16
2003	27
2004	77
2005	68
2006	26
2007	13
2008	8
2009	12
2010	8
2011	6
2012	3
2014	1
2017	2
2022	1
2023	1
2024	1

1

A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era..

Mohapatra R, Tran M, Gore JM, Spencer FA. Mohapatra R, et al. Am Heart J. 2005 Jul;150(1):19-26. doi: 10.1016/j.ahj.2005.02.012. Am Heart J. 2005. PMID: 16084146 Review.

2

Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.

Colwell C, Mouret P. Colwell C, et al. Semin Vasc Med. 2005 Aug;5(3):266-75. doi: 10.1055/s-2005-916166. Semin Vasc Med. 2005. PMID: 16123914 Review.

3

A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.

Eriksson BI, Arfwidsson AC, Frison L, Eriksson UG, Bylock A, Kälebo P, Fager G, Gustafsson D. Eriksson BI, et al. Thromb Haemost. 2002 Feb;87(2):231-7. Thromb Haemost. 2002. PMID: 11858482 Clinical Trial.

4

Ximelagatran: a new oral anticoagulant.

Hrebickova L, Nawarskas JJ, Anderson JR. Hrebickova L, et al. Heart Dis. 2003 Nov-Dec;5(6):397-408. doi: 10.1097/01.hdx.0000099777.39577.e8. Heart Dis. 2003. PMID: 14633322 Review.

5

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr; EXULT A Study Group. Francis CW, et al. N Engl J Med. 2003 Oct 30;349(18):1703-12. doi: 10.1056/NEJMoa035162. N Engl J Med. 2003. PMID: 14585938 Free article. Clinical Trial.

6

Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.

[No authors listed] [No authors listed] Prescrire Int. 2005 Aug;14(78):127-32. Prescrire Int. 2005. PMID: 16106594

7

[Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].

Selçuk H, Selçuk MT, Maden O. Selçuk H, et al. Anadolu Kardiyol Derg. 2007 Mar;7(1):54-8. Anadolu Kardiyol Derg. 2007. PMID: 17347079 Review. Turkish.

8

Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran.

Harenberg J, Ingrid J, Tivadar F. Harenberg J, et al. Isr Med Assoc J. 2002 Nov;4(11):1003-5. Isr Med Assoc J. 2002. PMID: 12489490 Free article. Clinical Trial.

9

Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).

Halperin JL; Executive Steering Committee, SPORTIF III and V Study Investigators. Halperin JL, et al. Am Heart J. 2003 Sep;146(3):431-8. doi: 10.1016/S0002-8703(03)00325-9. Am Heart J. 2003. PMID: 12947359 Clinical Trial.

10

Ximelagatran.

Choudhury A, Goyal D, Lip GY. Choudhury A, et al. Drugs Today (Barc). 2006 Jan;42(1):3-19. doi: 10.1358/dot.2006.42.1.893611. Drugs Today (Barc). 2006. PMID: 16511607 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

273 results

Results by year